Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

ARID1A, ARID1B, and ARID2 Mutations Serve as Potential Biomarkers for Immune Checkpoint Blockade in Patients With Non-Small Cell Lung Cancer.

Frontiers in immunology - 1 Jan 2021

Zhu Guangsheng, Shi Ruifeng, Li Yongwen, Zhang Zihe, Xu Songlin, Chen Chen, Cao Peijun, Zhang Hongbing, Liu Minghui, Pan Zhenhua, Liu Hongyu, Chen Jun

Abstract excerpt

Worldwide, non-small cell lung cancer (NSCLC) has the highest morbidity and mortality of all malignancies. The lack of responsiveness to checkpoint inhibitors is a central problem in the modern era of cancer immunotherapy, with the rapid development of immune checkpoint inhibitors (ICIs) in recent years. The human switch/sucrose nonfermentable (SWI/SNF) chromatin-remodeling complex has been reported to be...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to Clinical Decision-Making

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Decision Support Techniques

Share to Immune Checkpoint Inhibitors

Share to Nomograms

Share to Patient Selection

Share to Predictive Value of Tests

Share to Tumor Microenvironment

Source

Open in PubMed Open full text

Identifiers

PMID: 34512623
DOI: 10.3389/fimmu.2021.670040
PMCID: PMC8426508

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

ARID1A, ARID1B, and ARID2 Mutations Serve as Potential Biomarkers for Immune Checkpoint Blockade in Patients With Non-Small Cell Lung Cancer.PMID 34512623Read ↗

ARID1A mutations in lung cancer: biology, prognostic role, and therapeutic implications.Semantic proximity Read ↗

Mutational landscape of SWI/SNF complex genes reveal correlation to predictive biomarkers for immunotherapy sensitivity in lung adenocarcinoma patients.Semantic proximity Read ↗

ARID1B Deficiency Leads to Impaired DNA Damage Response and Activated cGAS-STING Pathway in Non-Small Cell Lung CancerSemantic proximity Read ↗

ARID1B Deficiency Leads to Impaired DNA Damage Response and Activated cGAS- STING Pathway in Non-Small Cell Lung CancerSemantic proximity Read ↗

SWI/SNF complex gene variations are associated with a higher tumor mutational burden and a better response to immune checkpoint inhibitor treatment: a pan-cancer analysis of next-generation sequencing data corresponding to 4591 casesSemantic proximity Read ↗

SWI/SNF complex gene variations are associated with a higher tumor mutational burden and a better response to immune checkpoint inhibitor treatment: a pan-cancer analysis of next-generation sequencing data corresponding to 4591 casesSemantic proximity Read ↗

Correlations of switch/sucrose nonfermentable complex mutations with clinical outcomes in advanced non-small cell lung cancer.Semantic proximity Read ↗

Subunits of ARID1 serve as novel biomarkers for the sensitivity to immune checkpoint inhibitors and prognosis of advanced non-small cell lung cancer.Semantic proximity Read ↗

Subunits of ARID1 serve as novel biomarkers for the sensitivity to immune checkpoint inhibitors and prognosis of advanced non-small cell lung cancer.Semantic proximity Read ↗

Mammalian SWI/SNF Complex Genomic Alterations and Immune Checkpoint Blockade in Solid Tumors.Semantic proximity Read ↗

Chromatin remodeling (SWI/SNF) complexes, cancer, and response to immunotherapySemantic proximity Read ↗

ARID1A serves as a receivable biomarker for the resistance to EGFR-TKIs in non-small cell lung cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.